These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27169683)

  • 1. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
    Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of different in vitro dissolution tests based on level A in vitro-in vivo correlations for fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Lebrun S; Cahay B; Brouwers A; Streel B; Cardot JM; Evrard B
    Eur J Pharm Biopharm; 2017 Mar; 112():18-29. PubMed ID: 27865930
    [No Abstract]   [Full Text] [Related]  

  • 4. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
    Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
    Hens B; Brouwers J; Corsetti M; Augustijns P
    Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
    Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
    Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
    Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
    Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D
    J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate.
    Sironi D; Rosenberg J; Bauer-Brandl A; Brandl M
    Eur J Pharm Sci; 2017 Jan; 96():20-27. PubMed ID: 27597143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
    Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
    Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation.
    Xiumin LI; Man GE; Minzi LU; Yinghua J; Dongqin Q
    Curr Drug Deliv; 2015; 12(3):308-13. PubMed ID: 26054534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution improvement of solid self-emulsifying drug delivery systems of fenofibrate using an inorganic high surface adsorption material.
    Shazly G; Mohsin K
    Acta Pharm; 2015 Mar; 65(1):29-42. PubMed ID: 25781702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA; Chalmers DK; Pouton CW; Porter CJH
    Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate.
    Kanaujia P; Ng WK; Tan RB
    J Microencapsul; 2014; 31(3):293-8. PubMed ID: 24156747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
    Mohsin K
    AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method.
    Xu H; Shi Y; Vela S; Marroum P; Gao P
    J Pharm Sci; 2018 Jan; 107(1):476-487. PubMed ID: 28666964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
    Cho YD; Park YJ
    Arch Pharm Res; 2014 Feb; 37(2):193-203. PubMed ID: 23754165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate.
    Hugo M; Kunath K; Dressman J
    Drug Dev Ind Pharm; 2013 Feb; 39(2):402-12. PubMed ID: 22591213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.